Table 1

Effects of LErafAON on liver enzymes and histology in CD2F1 micea

LErafAON dose (mg/kg)AST (units/liter)ALT (units/liter)Liver histology
Short-term response (n = 2)Long-term response (n = 3)Short-term response (n = 2)Long-term response (n = 3)Short-term responseLong-term response
5.099 ± 22130 ± 3237 ± 2130 ± 4Minimal histiocytic hepatitisNormal
15.0267 ± 145225 ± 72b56 ± 1449 ± 12Mild histiocytic hepatitisMild histiocytic hepatitis
25.0396c237 ± 114111c89 ± 75Mild-moderate histiocytic hepatitisModerate histiocytic hepatitis
35.0564 ± 209473 ± 78d161 ± 57218 ± 117eModerate-severe histiocytic hepatitisModerate histiocytic hepatitis
BL291 ± 26267 ± 114e78 ± 80134 ± 81Mild-moderate histiocytic hepatitisModerate histiocytic hepatitis
UT125 ± 12077 ± 2030 ± 1719 ± 15NormalNormal
  • a LErafAON was injected i.v. at indicated doses (n = 5) and clinical and histopathological evaluations were performed as described in “Materials and Methods.” Two animals from each group were intended sacrifices 48 h after the last dose (short-term response), and the remaining three animals were intended sacrifices 15 days after the last dose (long-term response). BL, blank liposome dose was equivalent to the lipid dose in 35.0 mg/kg LErafAON group. The values shown are mean ± SD.

  • b P < 0.03 compared with UT controls.

  • c n = 1.

  • d P < 0.001 compared with UT controls.

  • e P < 0.05 compared with UT controls.